Drugs in Development

ELND005, an amyloid beta aggregation inhibitor

The small molecule ELND005 is a beta amyloid anti-aggregation agent. In multiple Phase 1 clinical studies, ELND005 was found to be safe and well-tolerated at all doses and dosing regimens examined. No severe or serious adverse events were observed. ELND005 was also shown to be orally bioavailable, cross the blood-brain barrier and achieve levels in the brain and cerebral spinal fluid shown to be effective in animal models of Alzheimer’s disease. ELND005 is in a Phase 2 clinical study. The study is a randomized, double-blind, placebo-controlled, dose-ranging, safety and efficacy study in patients with mild to moderate Alzheimer’s disease.

 

ELND006 and ELND007

These agents are small molecule gamma secretase inhibitors. Our finding that functional gamma secretase inhibitors appear to reduce beta amyloid levels in the brain, published in the Journal of Neurochemistry in 2001, was an important step in this area of Alzheimer’s disease research. These unique molecules may affect the activity of gamma secretase in a substrate-specific manner.

 

ELND002

ELND002 is a PEGylated small molecule alpha 4 integrin inhibitor. This unique compound is being studied in clinical trials for the treatment of relapsing forms of multiple sclerosis. For more information regarding our clinical trial, please go to clinicaltrials.gov.   

Alzheimer's Immunotherapy (Bapineuzumab, AAB-002, ACC-001)

In September 2009, JANSSEN Alzheimer Immunotherapy, a subsidiary of Johnson & Johnson, acquired substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP), including bapineuzumab. 
 
For information about AIP, including clinical trials, please contact:

JANSSEN Alzheimer Immunotherapy (Dublin)
Treasury Building
Lower Grand Canal Street
Dublin 2, Ireland
Telephone: +353.1.709.4900
Fax: +353.1.709.4950
 
JANSSEN Alzheimer Immunotherapy Research & Development, LLC (South San Francisco)
700 Gateway Blvd
South San Francisco, CA 94080
Telephone: +1 650.794.2500; +1 888.381.4595
Fax: +1 650.794.2504